If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHemogenyx Pharmaceuticals Regulatory News (HEMO)

Share Price Information for Hemogenyx Pharmaceuticals (HEMO)

Share Price is delayed by 15 minutes
Get Live Data
770.00    20.00 (2.67%)
Bid:
731.00
Ask:
800.00
Spread: 69.00 (9.439%)
Market Cap: £52.36m
HEMO Live PriceLast checked at - London Stock Exchange

Intraday Hemogenyx Pharmaceuticals Share Chart

Director/PDMR Shareholding

12 Feb 2018 07:00

RNS Number : 5133E
Hemogenyx Pharmaceuticals PLC
12 February 2018
 

Hemogenyx Pharmaceuticals Plc 

("Hemogenyx" or the "Company")

 

Director / PDMR Shareholding

 

Hemogenyx Pharmaceuticals Plc (LSE: HEMO), the biotechnology company developing novel therapies to transform bone marrow and blood stem cell transplantation, announces that it has been advised that on 9 February 2018 Adrian Beeston, Non-Executive Director, purchased 200,000 ordinary shares of £0.01 each in the Company ("Ordinary Shares") at a price of 2.1p per share. Following this transaction Mr Beeston now has an interest in 6,331,969 Ordinary Shares, representing approximately 1.78 per cent. of the Company's issued share capital.

 

The Notification of Dealing Form provided in accordance with the requirements of MAR in relation to the transactions listed above are set out below:

 

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

 

1

 

Details of the person discharging managerial responsibilities / person closely associated

 

a)

 

Name

 

 

Adrian Beeston

 

2

 

Reason for the notification

 

a)

 

Position/status

 

 

Non-executive Director

 

b)

 

Initial notification /Amendment

 

 

Initial notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

 

Name

 

 

Hemogenyx Pharmaceuticals Plc

b)

 

LEI

 

 

n/a

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

a)

 

Description of the financial instrument, type of instrument

Ordinary shares of £0.01 each

Identification code

ISIN GB00BYX3WZ24

 

b)

 

Nature of the transaction

 

 

Purchase of Ordinary Shares

c)

 

Price(s) and volume(s)

 

 

 

 

 

Price(s)

Volume(s)

 

 

2.1p

200,000

 

 

 

 

 

d)

 

Aggregated information

- Aggregated volume

 N/A - single transaction

- Price

e)

 

Date of the transaction

 

 

9 February 2018

f)

 

Place of the transaction

 

 

London Stock Exchange

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
DSHBIGDDDDGBGIC
Date   Source Headline
27th Apr 20204:36 pmRNSPrice Monitoring Extension
27th Apr 20202:06 pmRNSSecond Price Monitoring Extn
27th Apr 20202:00 pmRNSPrice Monitoring Extension
22nd Apr 20204:40 pmRNSSecond Price Monitoring Extn
22nd Apr 20204:35 pmRNSPrice Monitoring Extension
22nd Apr 20202:05 pmRNSSecond Price Monitoring Extn
22nd Apr 20202:00 pmRNSPrice Monitoring Extension
22nd Apr 202011:00 amRNSCOVID-19 Project Initiated
21st Apr 20202:26 pmRNSApproval and Issuance of European Hu-PHEC Patent
2nd Apr 20202:05 pmRNSSecond Price Monitoring Extn
2nd Apr 20202:00 pmRNSPrice Monitoring Extension
28th Feb 20206:30 pmRNSTotal Voting Rights
20th Feb 20207:00 amRNSHEMO-CAR-T cells Effective Against AML in vivo
20th Feb 20207:00 amRNSHEMO-CAR-T cells Effective Against AML in vivo
11th Feb 20207:00 amRNSApproval and Issuance of U.S. Hu-PHEC Patent
31st Jan 20207:00 amRNSDirector/PDMR Shareholding
30th Jan 20202:05 pmRNSPlacing and Subscription to raise £650,000
15th Jan 202012:30 pmRNSHEMO's CAR-T Cells Effective Against AML in vitro
18th Nov 20197:00 amRNSOperational Update
12th Nov 20197:00 amRNSPresentation at the Investival Showcase
6th Nov 20197:00 amRNSPresentation at the NY Oncology Investor Conf.
23rd Oct 20197:00 amRNSResearch Agreement with Global Pharma Company
21st Oct 20197:00 amRNSPresentation at NY Stem Cell Foundation conference
30th Sep 20197:00 amRNSHalf-year Report
12th Sep 20197:00 amRNSHemogenyx scientific advisor receives Lasker Award
1st Aug 20197:00 amRNSTotal Voting Rights
12th Jul 20197:00 amRNSCDX Patent Application
3rd Jul 20197:00 amRNSDirector/PDMR Shareholding
28th Jun 201912:19 pmRNSResult of AGM
24th Jun 20197:00 amRNSDevelopment of ApbHC
12th Jun 20197:00 amRNSCDX Effective as Conditioning Therapeutic in vivo
5th Jun 20198:15 amRNSCDX Antibody is Effective against AML in vivo
30th May 20194:40 pmRNSSecond Price Monitoring Extn
30th May 20194:35 pmRNSPrice Monitoring Extension
30th May 20197:00 amRNSCDX Antibody is Effective against ALL in vitro
28th May 20197:00 amRNSPosting of Annual Report and Notice of AGM
15th May 20197:00 amRNSVariation of Terms of Warrant Instrument
1st May 20197:00 amRNSDirector/PDMR Shareholding
29th Apr 20193:10 pmRNSFinal Results for the Year Ended 31 December 2018
30th Jan 20197:00 amRNSPresentation at Cancer Immunotherapy Conference
7th Jan 20197:00 amRNSOperations Update
20th Dec 20187:00 amRNSDirectorate Change
5th Nov 20187:00 amRNSDirectorate Change & Appointment
22nd Oct 20187:00 amRNSOrgenesis collaboration for Hu-PHEC development
19th Oct 20187:00 amRNSCollaboration, License and Investment by Orgenesis
15th Oct 20187:00 amRNSCollaboration with Johnson & Johnson Innovation
28th Sep 20189:30 amRNSHalf-year Report
28th Sep 20187:00 amRNSChange of Adviser
3rd Sep 20187:00 amRNSHemogenyx to present at Oxford conference
27th Jun 201811:39 amRNSResult of AGM

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.